<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406142</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-17-0007-CTIL</org_study_id>
    <nct_id>NCT04406142</nct_id>
  </id_info>
  <brief_title>Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope - the VISUAL Method</brief_title>
  <acronym>VISUAL</acronym>
  <official_title>Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope - a Prospective, Multicenter Trial, Assessing the Feasibility of the VISUAL Method (Video Surfactant Administration Laryngoscopy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surfactant administration via thin catheter using a specially adapted video laryngoscope - a
      prospective, multicenter trial, assessing the feasibility of the VISUAL method (Video
      Surfactant Administration Laryngoscopy).

      The study will search for the number of attempts until surfactant is administrated,
      assessment of the infants' stability during the procedure, duration of the entire procedure,
      form laryngoscope insertion to surfactant administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators intend to assess the feasibility of surfactant administration
      via a thin catheter using a specially adapted video laryngoscope, with a groove designed to
      allow insertion of an endovascular catheter without the use of other instruments in the oral
      cavity (forceps ect.).

      The laryngoscope is manufactured by Peak Medic Ltd, Natania, Israel.

      Primary Endpoints

        1. - Number of attempts until surfactant is administrated

        2. - Assessment of the infants' stability during the procedure - saturation, bradycardia,
           tachycardia.

        3. - Duration of the entire procedure, form laryngoscope insertion to surfactants
           administration.

      4. Secondary Endpoints

        1. - Need of invasive mechanical ventilation in the next 24 hours.

        2. - Complications reports

        3. - Subjective procedure scale of assessment

        4. - Unexpected pitfalls reports

        5. - Safety assessment of the procedure
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Feasibility study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measures</measure>
    <time_frame>1 year</time_frame>
    <description>Success for surfactant administration - yes / no</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures 1</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of the infants' SPO2 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures 2</measure>
    <time_frame>1 year</time_frame>
    <description>Heart rate during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures 3</measure>
    <time_frame>1 year</time_frame>
    <description>Respiratory rate (breaths per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures 4</measure>
    <time_frame>1 year</time_frame>
    <description>number of attempts for vocal cords visualization (number)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures 5</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of the procedure (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures 6</measure>
    <time_frame>1 year</time_frame>
    <description>Need for mechanical ventilaton witin 24 hours following procedure (yes-no)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>treatment feasibility</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>feasibility, safety and effectiveness assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VISUAL</intervention_name>
    <description>thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy</description>
    <arm_group_label>treatment feasibility</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. - Premature infants with gestational age 30-36 weeks.

          2. - Diagnosis of respiratory distress syndrome

          3. - Spontaneously breathing with non-invasive positive pressure ventilation.

          4. - Maximal age 3 days.

        Exclusion Criteria:

          1. - Apgar score at 5 min &lt; 5

          2. - Need for chest compressions or medication upon delivery.

          3. - Evident major congenital malformation, metabolic or genetic disorders.

          4. - Clinical evidence of sepsis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan I Waisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neonatology, Carmel Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan I Waisman, MD</last_name>
    <phone>972-4-8250339</phone>
    <email>dwaisman@technion.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilla Cohen, MPH</last_name>
    <phone>972-4-8250843</phone>
    <email>hillaco@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neonatology, Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Waisman, MD</last_name>
      <phone>+972506265525</phone>
      <email>dwaisman@netvision.net.il</email>
    </contact>
    <investigator>
      <last_name>Dan Waisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carmel Medical Center</investigator_affiliation>
    <investigator_full_name>Dany Waisman</investigator_full_name>
    <investigator_title>Director of the Newborn Unit Department of Neonatology</investigator_title>
  </responsible_party>
  <keyword>respiratory distress syndrome</keyword>
  <keyword>videolaryngoscopy</keyword>
  <keyword>newborn infant</keyword>
  <keyword>premature newborn infant</keyword>
  <keyword>surfactant administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

